Mumbai, 5th August, 2020: The cases of COVID-19 is increasing significantly globally and India too is affected with around 50,000 new cases being added on a daily basis. In this backdrop, Alkem Laboratories Ltd. (Alkem) has launched Favipiravir under the brand name “Alfluenza” in India for the management of mild to moderate cases of COVID-19. Favipiravir is approved by DCGI (Drug Controller General of India) for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.
About Alkem Laboratories Ltd.
Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA data March 2020). The Company also has presence in more than 40 international markets, with the United States being its key focus market.
For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com
To read more Press Release articles, click here.